ImageneBio, Inc. Operating Expenses
ImageneBio, Inc. (IMA) reported Operating Expenses of $11.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- ImageneBio, Inc. operating expenses for the quarter ending 2026-06-30 was $11.78M, a 60.15% increase year-over-year.
- ImageneBio, Inc. operating expenses for the quarter ending 2026-03-31 was $12.08M, a 77.76% increase year-over-year.
- ImageneBio, Inc. operating expenses for the quarter ending 2025-12-31 was $8.50M, a 38.46% increase year-over-year.
- ImageneBio, Inc. operating expenses for the quarter ending 2025-09-30 was $26.59M, a 380.38% increase year-over-year.
- ImageneBio, Inc. operating expenses for fiscal 2025 was $49.25M, a 21.61% increase from fiscal 2024.
- ImageneBio, Inc. operating expenses for fiscal 2024 was $40.50M, a 52.11% decline from fiscal 2023.
- ImageneBio, Inc. operating expenses for fiscal 2023 was $84.58M, a 2.25% decline from fiscal 2022.
- ImageneBio, Inc. operating expenses for fiscal 2022 was $86.52M, a 32.86% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.78M 10-Q · filed 2026-08-05 | $23.86M 10-Q · filed 2026-08-05 | $32.37M derived: sum of 3 quarters · filed 2026-08-05 | $58.96M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $12.08M 10-Q · filed 2026-05-07 | $20.58M derived: sum of 2 quarters · filed 2026-05-07 | $47.18M derived: sum of 3 quarters · filed 2026-05-07 | $54.53M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $35.10M derived: sum of 2 quarters · filed 2026-03-10 | $42.46M derived: sum of 3 quarters · filed 2026-08-05 | $49.25M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | $26.59M 10-Q · filed 2025-11-12 | $33.95M derived: sum of 2 quarters · filed 2026-08-05 | $40.75M 10-Q · filed 2025-11-12 | $46.89M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $7.36M 10-Q · filed 2026-08-05 | $8.75M 10-Q · filed 2025-07-24 | $14.15M 10-Q · filed 2026-08-05 | $19.54M 10-Q · filed 2025-07-24 | $20.30M derived: sum of 3 quarters · filed 2026-08-05 | $25.83M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $6.79M 10-Q · filed 2026-05-07 | $10.79M 10-Q · filed 2025-05-08 | $12.94M derived: sum of 2 quarters · filed 2026-05-07 | $18.47M derived: sum of 3 quarters · filed 2026-05-07 | $34.30M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $11.68M derived: sum of 2 quarters · filed 2026-03-10 | $27.50M derived: sum of 3 quarters · filed 2026-03-10 | $40.50M 10-K · filed 2026-03-10 | $58.97M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $5.54M 10-Q · filed 2025-11-12 | $12.41M 10-Q · filed 2024-11-07 | $21.36M derived: sum of 2 quarters · filed 2025-11-12 | $34.36M 10-Q · filed 2025-11-12 | $46.46M 10-Q · filed 2024-11-07 | $62.15M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $15.82M 10-Q · filed 2025-07-24 | $34.05M 10-Q · filed 2025-07-24 | $56.62M derived: sum of 3 quarters · filed 2025-07-24 | $77.30M derived: sum of 4 quarters · filed 2025-07-24 | ||||
| 2024-03-31 | $18.23M 10-Q · filed 2025-05-08 | $40.79M derived: sum of 2 quarters · filed 2025-05-08 | $61.48M derived: sum of 3 quarters · filed 2025-05-08 | $81.97M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $22.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $43.26M derived: sum of 2 quarters · filed 2025-03-06 | $63.75M derived: sum of 3 quarters · filed 2025-03-06 | $84.58M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $20.69M 10-Q · filed 2024-11-07 | $41.18M derived: sum of 2 quarters · filed 2024-11-07 | $62.01M 10-Q · filed 2024-11-07 | $82.57M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $20.49M 10-Q · filed 2024-08-08 | $41.32M 10-Q · filed 2024-08-08 | $61.89M derived: sum of 3 quarters · filed 2024-08-08 | $86.16M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $20.83M 10-Q · filed 2024-05-13 | $41.39M derived: sum of 2 quarters · filed 2024-05-13 | $65.67M derived: sum of 3 quarters · filed 2024-05-13 | $87.00M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $20.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $44.84M derived: sum of 2 quarters · filed 2024-03-12 | $66.17M derived: sum of 3 quarters · filed 2024-03-12 | $86.52M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $24.28M 10-Q · filed 2023-11-09 | $45.61M derived: sum of 2 quarters · filed 2023-11-09 | $65.96M 10-Q · filed 2023-11-09 | $83.38M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $21.33M 10-Q · filed 2023-08-10 | $41.68M 10-Q · filed 2023-08-10 | $59.10M derived: sum of 3 quarters · filed 2023-08-10 | $77.37M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $20.35M 10-Q · filed 2023-05-15 | $37.77M derived: sum of 2 quarters · filed 2023-05-15 | $56.04M derived: sum of 3 quarters · filed 2023-05-15 | $72.28M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $17.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $35.69M derived: sum of 2 quarters · filed 2023-03-14 | $51.93M derived: sum of 3 quarters · filed 2023-03-14 | $65.12M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $18.27M 10-Q · filed 2022-11-07 | $34.50M derived: sum of 2 quarters · filed 2022-11-07 | $47.70M 10-Q · filed 2022-11-07 | $73.82M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $16.24M 10-Q · filed 2022-08-11 | $29.43M 10-Q · filed 2022-08-11 | $55.55M derived: sum of 3 quarters · filed 2022-08-11 | $64.61M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $13.19M 10-Q · filed 2022-05-12 | $39.31M derived: sum of 2 quarters · filed 2022-05-12 | $48.37M derived: sum of 3 quarters · filed 2022-05-12 | $56.51M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $26.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $35.18M derived: sum of 2 quarters · filed 2022-03-17 | $43.31M derived: sum of 3 quarters · filed 2022-03-17 | $53.71M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $9.06M 10-Q · filed 2021-11-10 | $17.19M derived: sum of 2 quarters · filed 2021-11-10 | $27.59M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $8.13M 10-Q · filed 2021-08-12 | $18.53M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $10.40M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |